Trials / Sponsors / Arcturus Therapeutics, Inc.

Arcturus Therapeutics, Inc.

Industry · 13 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis Cystic Fibrosis, CFTR Gene Mutation	Phase 2	2024-12-12
Completed	Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults Influenza, Human	Phase 1	2024-12-10
Recruiting	A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD	Phase 2	2024-11-04
Completed	Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines COVID-19	Phase 3	2024-03-27
Completed	Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine Influenza, Human	Phase 1	2024-01-22
Completed	Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibros Cystic Fibrosis	Phase 1	2023-02-15
Terminated	Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerabilit Ornithine Transcarbamylase Deficiency, OTC Deficiency, OTCD	Phase 2	2022-10-17
Completed	A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults COVID-19, SARS-CoV-2 Infection, Corona Virus Infection	Phase 1 / Phase 2	2021-08-30
Terminated	A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults Covid19, SARS-CoV Infection, Corona Virus Infection	Phase 2	2021-01-07
Terminated	Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 SARS-CoV-2	Phase 2	2021-01-04
Completed	Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency	Phase 1	2020-11-03
Completed	Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects SARS-CoV-2	Phase 1 / Phase 2	2020-08-04
Completed	Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects Ornithine Transcarbamylase Deficiency	Phase 1	2020-06-01